A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
EvolveImmune United, Inc
Seagen Inc.
Pfizer
IDEAYA Biosciences
Rondo Therapeutics
Neonc Technologies, Inc.
Novartis
MacroGenics
Innate Pharma
Mayo Clinic
NeoTX Therapeutics Ltd.
DualityBio Inc.
Incyte Corporation
Incyte Corporation
UNICANCER
Cofactor Genomics, Inc.
Seagen Inc.
Molecular Templates, Inc.
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Jules Bordet Institute
Atreca, Inc.
Gossamer Bio Inc.
OHSU Knight Cancer Institute
Hoag Memorial Hospital Presbyterian